Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients with PDAC have mutations in KRAS, which unfortunately remains an ineffectual target. Our strategy here is to target KRAS downstream effectors PI3K and mTOR. In this study,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ning, Changwen, Liang, Min, Liu, Shuang, Wang, Guan, Edwards, Holly, Xia, Yang, Polin, Lisa, Dyson, Gregory, Taub, Jeffrey W., Mohammad, Ramzi M., Azmi, Asfar S., Zhao, Lijing, Ge, Yubin
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546481/
https://ncbi.nlm.nih.gov/pubmed/28574828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17869
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados